Christopher Bryan - Algernon Pharmaceuticals VP Operations
| AGNPF Stock | USD 0.06 0 3.16% |
Insider
Christopher Bryan is VP Operations of Algernon Pharmaceuticals
| Age | 40 |
| Phone | 604 398 4175 |
| Web | https://algernonpharmaceuticals.com |
Algernon Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.526) % which means that it has lost $0.526 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.0923) %, meaning that it generated substantial loss on money invested by shareholders. Algernon Pharmaceuticals' management efficiency ratios could be used to measure how well Algernon Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Dr MBA | Cellectis SA | 46 | |
| Paul CPA | Mosaic Immunoengineering | 55 | |
| Nicole Steinmetz | Mosaic Immunoengineering | 43 | |
| Greg Leszczynski | Covalon Technologies | N/A | |
| George Hill | Ascletis Pharma | 72 | |
| Ming CPA | Ascletis Pharma | N/A | |
| Elaine Zhang | Covalon Technologies | N/A | |
| Jason Gorel | Covalon Technologies | N/A | |
| Ron Hebert | Covalon Technologies | N/A | |
| Yuemei Yan | Ascletis Pharma | 53 | |
| Pascalyne Wilson | Cellectis SA | N/A | |
| Hejingdao Wu | Ascletis Pharma | 49 | |
| John MBA | Ascletis Pharma | N/A | |
| MSc MSc | Cellectis SA | 54 | |
| Florian M | GH Research PLC | 55 | |
| Magnus Halle | GH Research PLC | 27 | |
| Jay Carlson | Mosaic Immunoengineering | N/A | |
| Gerry Arambula | Covalon Technologies | N/A | |
| Marvin MD | Mosaic Immunoengineering | 79 | |
| Joseph MPH | Mosaic Immunoengineering | 50 | |
| Jinzi Wu | Ascletis Pharma | 60 | |
Management Performance
| Return On Equity | -1.09 | |||
| Return On Asset | -0.53 |
Algernon Pharmaceuticals Leadership Team
Elected by the shareholders, the Algernon Pharmaceuticals' board of directors comprises two types of representatives: Algernon Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Algernon. The board's role is to monitor Algernon Pharmaceuticals' management team and ensure that shareholders' interests are well served. Algernon Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Algernon Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christopher Moreau, CEO Director | ||
| Christopher Bryan, VP Operations |
Algernon Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Algernon Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.09 | |||
| Return On Asset | -0.53 | |||
| Current Valuation | 3.03 M | |||
| Shares Outstanding | 2.41 M | |||
| Shares Owned By Insiders | 1.70 % | |||
| Shares Owned By Institutions | 14.73 % | |||
| Price To Book | 1.02 X | |||
| EBITDA | (6.02 M) | |||
| Net Income | (6.05 M) | |||
| Cash And Equivalents | 872.84 K |
Currently Active Assets on Macroaxis
Other Information on Investing in Algernon OTC Stock
Algernon Pharmaceuticals financial ratios help investors to determine whether Algernon OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Algernon with respect to the benefits of owning Algernon Pharmaceuticals security.